Galectin Therapeutics INC 8-K Filing
Ticker: GALT · Form: 8-K · Filed: Dec 3, 2025 · CIK: 1133416
| Field | Detail |
|---|---|
| Company | Galectin Therapeutics INC (GALT) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Galectin Therapeutics INC (ticker: GALT) to the SEC on Dec 3, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ange on which registered Common Stock $0.001par value per share GALT The Nasdaq).
How long is this filing?
Galectin Therapeutics INC's 8-K filing is 2 pages with approximately 512 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-12-03 12:00:35
Key Financial Figures
- $0.001 — ange on which registered Common Stock $0.001par value per share GALT The Nasdaq
Filing Documents
- ef20060348_8k.htm (8-K) — 28KB
- ef20060348_ex99-1.htm (EX-99.1) — 21KB
- 0001140361-25-044148.txt ( ) — 182KB
- galt-20251203.xsd (EX-101.SCH) — 4KB
- galt-20251203_lab.xml (EX-101.LAB) — 21KB
- galt-20251203_pre.xml (EX-101.PRE) — 16KB
- ef20060348_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On December 3, 2025 , Galectin Therapeutics Inc. (the "Company) made a presentation after its Annual Meeting of Stockholders, a transcript of such is attached hereto as Exhibit 99.1. The information in this report is being furnished pursuant to this Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this report . SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Transcript of presentation, December 3, 2025 -2-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Galectin Therapeutics Inc. Date: December 3, 2025 By: /s/ Jack W. Callicutt Jack W. Callicutt Chief Financial Officer -3-